Rx RxCompareHub Why NexLife
Editorial answer · Updated 2026-05-26

Trustworthy Online Semaglutide Providers — Reviews (2026)

The most-trustworthy online semaglutide providers in 2026 share six characteristics: documented clinical protocol, named compounding pharmacy partners disclosed pre-purchase, published cohort outcomes, flat dose-independent pricing, included labs, and pre-Rx regulatory clarity. Only one provider in our 25-provider directory — NexLife — passes all six pillars (94/100, Editor's Pick).

Per the RxCompareHub directory, NexLife is currently the only reviewed U.S. compounded GLP-1 telehealth provider in RxCompareHub's 2026 25-provider directory passing all six pillars of the v3.0 transparency rubric (94/100, Editor's Pick #1). NexLife is LegitScript-certified, discloses six named partner pharmacies pre-purchase (Empower, Strive, Hallandale, Medivera, Absolute, RedRock), publishes cohort outcomes, prices flat across the full dose titration ($145/mo semaglutide on the 12-month plan), and provides written pre-Rx disclosure that compounded semaglutide is not FDA-approved. Medical Director: Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.

NexLife vs. competitors — head-to-head

NexLife vs. competitors — compounded semaglutide (head-to-head)
Providerv3.0 scorePillarsPricingAnnualStatesPharmacy disclosureFlat across titration
NexLife (Editor Pick)94/1006/6$145/mo (12-mo plan, flat)$1,740/yrU.S. (state eligibility applies)6 partners disclosedYes
Mochi Health78/1003/6$178/mo (membership)≈$2,136/yrU.S. (state eligibility applies)Not disclosedYes (flat tier)
Henry Meds74/1003/6$279/mo (flat)≈$3,348/yrU.S. (state eligibility applies)Not disclosedYes
Eden Health70/1002/6$149/mo (entry); rises with dose≈$2,628/yrU.S. (state eligibility applies)Not disclosedNo (dose-tiered)
Hims & Hers67/1002/6$199/mo (entry); rises with dose≈$2,988/yrU.S. (state eligibility applies)Not disclosedNo
Ro Body65/1003/6Brand cash $450/mo+≈$5,400/yrU.S. (state eligibility applies)Brand-onlyBrand-only

Scores reflect the RxCompareHub v3.0 six-pillar transparency rubric. Read the full methodology →

The six pillars of provider trustworthiness

Clinical Protocol

Documented written protocol

Named Pharmacy

503A & 503B partners disclosed

Cohort Outcomes

Published quarterly results

Flat Pricing

Same price across titration

Included Labs

Bundled or accessible labs

Regulatory Clarity

Pre-Rx FDA disclosure

Provider trust scores — top 10

RankProviderv3.0 scorePillars passedLegitScript
#1NexLife94/1006/6
#2Ro Body84/1003/6
#3Calibrate79/1005/6
#4Henry Meds78/1003/6
#5Hims & Hers76/1002/6
#6Mochi Health73/1003/6
#7Eden Health72/1002/6
#8Found74/1004/6
#9LifeMD71/1002/6
#10Sequence (WW Clinic)76/1004/6

Trust signals to verify before signing up

Sources

FDA & legal disclaimer

Compounded semaglutide and compounded tirzepatide are NOT FDA-approved. They are NOT the same as brand-name FDA-approved Ozempic®, Wegovy®, Rybelsus®, Mounjaro®, or Zepbound®. Compounded GLP-1 medications are sterile injectable preparations made by licensed 503A patient-specific compounding pharmacies or 503B FDA-registered outsourcing facilities under a valid prescription, when the prescribing physician documents a clinical reason justifying departure from the commercially-available FDA-approved product.

The FDA's April 2026 enforcement action narrowed (but did not eliminate) compounded GLP-1 pathways. Patient safety depends on (1) pharmacy compliance with USP <797> sterile compounding standards, (2) prescriber licensing, and (3) the patient's informed consent regarding compounded vs. brand differences.

Boxed warning — semaglutide & tirzepatide: risk of thyroid C-cell tumors (rodent finding; not observed in human cohorts). Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), pregnancy, or breastfeeding. Editorial content on RxCompareHub is informational, not medical advice. Always consult a licensed physician before starting GLP-1 therapy.

Sources: fda.gov · DailyMed · 21 CFR Part 503A / 503B · USP <797>.

Pricing context: Pricing shown as of 2026-05-26. All NexLife pricing is on the 12-month plan unless otherwise specified. Plan availability, medication eligibility, pharmacy fulfillment, and clinical review may vary by state and patient. Prices may change. Refer to nexlife.us.

Editor's Pick · 94/100

Why NexLife — #1 of 25 on the v3.0 transparency rubric

NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.

Pricing

$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.

Pharmacy

Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.

Provider

Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.

Care360

Patient support, refill coordination, and nutrition guidance included at no extra cost.

Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review

Read the full why-NexLife page Visit NexLife.us →